Investors who bought ZTS shares between January 14, 2025 and May 6, 2026 have until July 27, 2026 to seek lead plaintiff status in the New York case.
Zoetis Inc. is facing a securities fraud class action filed in the United States District Court for the Southern District of New York on behalf of investors who purchased or acquired its securities between January 14, 2025 and May 6, 2026. The complaint alleges the company made materially false or misleading statements, or omitted material facts, about product demand and competitive pressures affecting parts of its Companion Animal business. The filing says prescription growth and use of Librela, a pain treatment for dogs, weakened after FDA (U.S. Food and Drug Administration) safety warnings about serious neurological complications, while Simparica Trio and the dermatology products Apoquel and Cytopoint lost market share to competitors. After Zoetis reported 2026 first-quarter results on May 7, 2026 showing a significant decline across its Companion Animal business, the stock fell 21.5%, the release said. Investors have until July 27, 2026 to seek appointment as lead plaintiff in the case, captioned City of Ann Arbor Retiree Health Care Benefit Plan & Trust v. Zoetis Inc., No. 26-cv-04401 (S.D.N.Y.).